B of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $50
Agios Pharmaceuticals Inc AGIO
$32.58
▼ -0.97%
($-0.32)
Open
$32.93
Prev Close
$32.90
Day Range
$32.54 – $33.33
52W Range
$22.24 – $46.00
Market Cap
$1.95B
Beta
0.65
EPS (TTM)
$-7.01
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2013-07-24 |
| Shares Out. | 59,470,000 |
| Website | agios.com/ ↗ |
| Phone | 13026587581 |
| Employees | 540 |
| Revenue | $44.7M |
| Gross Profit | $41.7M |
| Net Income | -$100.7M |
| Free Cash Flow | -$365.3M |
| Total Assets | $1.11B |
| Total Liabilities | $82.4M |
| Equity | $1.03B |
About Agios Pharmaceuticals Inc
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Agios Pharmaceuticals Inc is a publicly traded company under the ticker symbol AGIO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-09-01)